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We are being questioned by our colleagues
and patients about a paper published in the
Brazilian Journal of Medical and Biological
Research by Coimbra and Junqueira (1). The
authors analyzed the effect of oral vitamin
B2 (riboflavin) and the dietary restriction of
red meat in 31 patients with Parkinson’s
disease (PD). The authors found that the
dietary intervention and the prescription of
riboflavin induced a significant improvement
in the clinical condition of their patients and
stated that this regimen should be recom-
mended to PD patients. In our opinion, this
article has many methodological problems,
which were surprisingly neglected by this
peer-reviewed journal.
The authors made an open-label experi-
ment not controlled with placebo. They se-
lected the patients, evaluated them, recom-
mended the dietary restriction, and prescribed
vitamin B2. At the end of a 6-month period
the authors themselves reevaluated the pa-
tients and concluded for an improvement on
motor scales. This type of non-blinded ex-
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periment can lead to biased estimated differ-
ences between pre- and post-therapeutic in-
tervention. In addition, there would have
been no ethical problems if placebo tablets
had been administered to some of the pa-
tients since the conventional treatment of PD
could have been maintained in both groups.
Patients who were instructed to refrain
from red meat should be warned about re-
ceiving another source of protein to prevent
malnutrition. It is well known that protein,
especially neutral amino acids, in the small
intestine and blood stream competes with
the intestinal absorption and with the brain
penetration of levodopa (2,3). Thus, it may
be speculated that the putative motor im-
provement found in PD patients under di-
etary protein restriction could be attributed
to the increased bioavailability of levodopa
in the brain. To minimize this bias, the au-
thors should have recommended to their pa-
tients not to take their oral levodopa doses
together with protein intake in the evaluation
prior to vitamin B2 administration and to
dietary intervention.
The authors did not report in their paper
the reasons why 12 patients dropped out of
the study. We do not know if there were
adverse effects or if the patients experienced
worsening of their clinical status. Also, the
authors only analyzed the outcomes of the
19 patients who remained on the dietary and
vitamin B2 regimen. It is highly recom-
mended in good scientific practice to ana-
lyze the outcomes including the data for
patients who dropped out (intention-to-treat
analysis).
Serum vitamin B2 levels in PD patients
were compared with those of 10 patients
with “dementia”. We know that “dementia”
is too generic a term and the authors do not
report the etiology of the disease in the 10
“demented” patients, which could obviously
interfere with the serum measurements of
vitamin B2. There are different criteria to
establish the diagnosis of dementia and the
authors did not disclose their criteria. Pa-
tients with memory complaints or even with
established dementia usually take oral multi-
vitamin preparations and this could also in-
terfere with the blood measurements, i.e.,
demented patients could in fact have high
vitamin B2 levels and PD patients could
have normal levels. The authors do not men-
tion if there is a study reporting the normal
range of blood vitamin B2 levels in a Brazil-
ian population. As far as we know, such a
study has not been done.
The main outcome measure used was a
new motor scale created by the authors of the
paper. They made a modification to the
Hoehn and Yahr scale, which is not used to
rate motor performance but to rate PD pa-
tients at five different stages. Motor perfor-
mance is best evaluated by the Unified Park-
inson’s Disease Rating Scale, which is a
validated and widely used scale (4). If the
authors wished to use their own scale they
should have validated it before collecting the
data.
The authors do not report if they evalu-
ated the patients during the “off” or “on”
state of the levodopa effect. Fluctuation of
motor performance is observed in more than
50% of the patients after five years of treat-
ment and an uncontrolled motor status evalu-
ation of the patients at baseline and after 6
months would be an important source of
bias.
Previous epidemiological studies with
case-control methodology have failed to dem-
onstrate any correlation between life-style or
food habits and Parkinson’s disease (5-7).
There is no scientific evidence correlating
vitamin B2 or protein consumption and Park-
inson’s disease in previous well-controlled
studies (8,9) analyzing a much higher num-
ber of individuals than the 31 patients stud-
ied by Coimbra and Junqueira (1).
In summary, there is no current scientific
evidence that vitamin B2 consumption and
dietary red meat restriction can benefit pa-
tients with Parkinson’s disease.
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We have reported a steady and progres-
sive improvement of motor capacity in 19
sporadic Parkinson’s disease (PD) patients
treated with high doses (30 mg orally every
8 h) of riboflavin plus elimination of dietary
red meat for 6 months (1). The treatment was
based on the following preliminary observa-
tions: I) 31 of 31 consecutively evaluated PD
patients were found to have an altered en-
zyme glutathione reductase activation coef-
ficient (EGR-AC) and low plasma levels of
flavin adenine dinucleotide (FAD) compared
to the internationally determined normal
range of FAD (125-300) and to local non-PD
patients suffering from other neurodegen-
erative conditions (dementia without a clini-
cal history or computed tomography scan
images compatible with stroke), and II) 19
PD patients were found to consume large
quantities of red meat (2,044 ± 1,439 g/
week) compared with 19 sex-matched con-
trols of similar age from the same social
environment (789 ± 509 g/week). Since all
PD patients had a normal dietary content of
riboflavin, we proposed that I) PD patients
may be a subset of the large group of indi-
References
1. Coimbra CG & Junqueira VBC (2003). High doses
of riboflavin and the elimination of dietary red
meat promote the recovery of some motor func-
tions in Parkinson’s disease patients. Brazilian
Journal of Medical and Biological Research, 36:
1409-1417.
2. Pare S, Burr SI & Ross SE (1992). Effect of day-
time protein restriction on nutrient intakes of free-
living Parkinson’s disease patients. American
Journal of Clinical Nutrition, 55: 701-707.
3. Simon N, Gantcheva R, Bruguerolle B & Viallet F
(2004). The effects of a normal protein diet on
levodopa plasma kinetics in advanced Parkinson’s
disease. Parkinsonism and Related Disorders, 10:
137-142.
4. Fahn S, Elton RL & Members of the UPDRS De-
velopment Committee (1987). Unified Parkinson’s
Disease Rating Scale. In: Fahn S, Marsden CD,
Calne DB & Goldstein M (Editors), Recent Devel-
opments in Parkinson’s Disease. Vol. 2. MacMillan
Health Care Information, Florham Park, NJ, USA,
153-164.
5. Baldereschi M, DiCarlo A, Vanni P, Ghetti A,
Carbonin P, Amaducci L & Inzitani D (2003). Italian
longitudinal study on aging working group. Life-
style related risk factors for Parkinson’s disease:
a populational study. Acta Neurologica Scandina-
vica, 108: 239-244.
6. Tsai CH, Lo SK, See LC, Chen HZ, Chen RS, Weng
YH, Chang FC & Lu CS (2002). Environmental risk
factors of young onset Parkinson’s disease. Clini-
cal Neurology and Neurosurgery, 104: 328-333.
7. Tanner CM (1994). Epidemiological clues to the
cause of Parkinson’s disease. In: Marsden CD &
Fahn S (Editors), Movement Disorders 3. Butter-
worth-Heinemann, Oxford, UK, 124-146.
8. Golbe LI, Farrel TM & Davis PH (1988). Case-
control study of early life dietary factors in Park-
inson’s disease. Archives of Neurology, 45: 350-
353.
9. Abbot RD, Ross GW, White CR, Sanderson WT,
Burchfiel CM, Kashon M, Sharp DS, Masaki KH,
Curb JD & Petrovitch H (2003). Environment, life-
style, and physical precursors of clinical Park-
inson’s disease: recent findings from the Hono-
lulu-Asia aging study. Journal of Neurology, 250
(Suppl 3): III-30-III-39.
1Setor de Neurologia, Hospital do Servidor Público Municipal de São Paulo, São Paulo, SP, Brasil
2Departamento de Neurologia e Neurocirurgia, and 3Disciplina de Geriatria, Departamento de
Medicina, Centro de Estudos do Envelhecimento, Universidade Federal de São Paulo, São Paulo,
SP, Brasil
4VITÆ - Cromatografia Líquida em Análises Clínicas S/C Ltda., São Paulo, SP, Brasil
C.G. Coimbra1,2 and V.B.C. Junqueira3,4
Response to the Comments of H.B. Ferraz et al.
1300
Braz J Med Biol Res 37(9) 2004
Concepts and Comments
viduals (10-15% of the general population)
expressing flavokinase (FK) with low sub-
strate affinity (poor absorbers of vitamin B2;
Ref. 2), and II) a high dietary red meat
consumption might trigger PD in predis-
posed individuals (expressing altered FK). A
review of the metabolic pathways requiring
the participation of both vitamin B2 active
forms (flavin mononucleotide and FAD) in-
dicated that the association of low ribofla-
vin absorption and high dietary red meat
consumption (high dietary hemin produc-
tion) might account for most (if not all)
neurochemical changes reported in PD in-
cluding glutathione depletion, impaired mi-
tochondrial complex I activity, mtDNA mu-
tations, disturbed iron metabolism, and
6(OH)dopamine formation (1).
By searching the current medical litera-
ture, Ferraz and associates might readily be-
come familiar with countless preliminary
studies which have been subsequently con-
firmed by larger and better controlled re-
search. The two consecutive articles by
Schoenen et al. (3,4) on the effects of high
doses of riboflavin on migraine may afford
an appropriate example. Preliminary reports
are commonly submitted to communicate
novel findings of potentially large benefit:
further research by others is thus facilitated.
Our initial report (1) was clearly presented
as preliminary work being part of ongoing
research.
A placebo effect is highly unlikely to
account for our results. Goetz et al. (5) ob-
served placebo-associated motor improve-
ments in only 16% of 105 PD subjects evalu-
ated at 4, 12 and 24 weeks of treatment, and
demonstrated that none of them showed im-
provement at all three evaluations. Their
observations contrast sharply with the ini-
tially rapid and then slowly progressive im-
provement found in all (100%) 19 PD pa-
tients in our own study (1). All patients were
fully informed about the meaning of “red
meat” and unequivocally advised to replace
it with another protein source. The timing of
levodopa administrations relative to meals
did not change during treatment and would
not explain the motor improvement found
between pre- and post-therapeutic interven-
tion. Now, after more than 18 months of
sustained treatment, none of our 19 patients
has experienced any deterioration of motor
capacity, and some have experienced further
motor improvement, although no additional
patient (apart from the initial 3 subjects) has
become symptom-free.
None of our initial 31 patients “dropped
out” of the study: 12 were excluded (by the
time the manuscript was submitted to this
journal, 2 of them had bone fractures that
prevented adequate motor evaluation, and
one died of metastasis from thyroid carcino-
ma - all 3 before completing 3 months of
therapy; the remaining 9 patients took erratic
daily doses of riboflavin - confirmed by
uncorrected EGR-AC and plasma FAD, or
did not comply with full elimination of di-
etary red meat, or had recently initiated the
treatment). There is long established evi-
dence (6) that orally administered riboflavin
is non-toxic (doses higher than 30 mg lead to
decreased net absorption), and much higher
doses (400 mg/day) have been safely given
to humans (3,4).
Heterogeneous control groups (composed
of patients suffering from different diseases)
have long been employed in clinical research
to establish whether a particular feature dif-
ferentiates a specific disease from others. In
addition, researchers may be dealing with a
heterogeneous group of neurodegenerative
diseases even when the currently employed
clinical diagnostic criteria for dementia of
the Alzheimer type are strictly fulfilled with-
out a brain tissue biopsy. Our study has
demonstrated that lower plasma concentra-
tions of FAD differentiate PD patients from
a clearly defined group of subjects with neu-
rodegenerative disorders without Parkin-
sonism. Moreover, when the levels found in
both groups of Brazilian patients were com-
pared with the internationally determined
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normal range of plasma FAD concentrations
and EGR-AC levels, we observed deficient
riboflavin status in all 31 consecutively evalu-
ated PD patients but in only 3 of 10 control
subjects. Therefore, the lack of population
studies addressing the normal range of FAD
among Brazilian inhabitants does not invali-
date our data. In addition, none of our PD or
control patients was malnourished or taking
tablets containing riboflavin. Therefore, when
analyzing the ethical issues involved in us-
ing placebo tablets in control groups of PD
patients during blinded studies, one should
consider the risk of aggravating permanent
neurological deficits by postponing the cor-
rection of documented riboflavin deficiency.
The 5 consecutive stages reported by
Hoehn and Yahr (7) are specifically based
on the progressive motor disabilities of PD
patients and on nothing else. Their validated
scale has been widely used to characterize
the degree of motor deterioration of PD pa-
tients. In our own percent rating system we
followed the same sequence of events, al-
though fragmented so as to detect motor
improvements in a more sensitive manner.
For instance, late stage IV (nearly full de-
pendence for daily care) was differentiated
from early stage IV (assistance required for
only the few most delicate or difficult items
like shaving and putting on socks).
Because only some of our patients were
in the advanced disease stage exhibiting the
“on-off” phenomenon, all patients were uni-
formly rated early in the morning, prior to
the earliest administration of symptomatic
drugs for PD. This timing usually coincides
with the “off” state for those with advanced
PD showing motor fluctuations and dyskine-
sias related to levodopa therapy.
All studies cited by Ferraz and associates
(their Refs. 5 to 9), presented to contest our
results, surprisingly contain no data on red
meat consumption (as distinguished from
the general protein consumption), labora-
tory evaluation of vitamin B2 status or the
effects of high doses of riboflavin on PD
patients. Two of them (their Refs. 5 and 6)
did not even inquire about food habits, and
in one (their Ref. 8) the authors confined
their inquiry to “food and vegetables eaten
raw, with seeds that are either swallowed or
scraped with the teeth” in a search for a heat-
labile component similar to that found in the
seeds of the cycad plant which grows only in
Guam and neighboring islands. Abbot et al.
(their Ref. 9) reported a similar daily intake
of riboflavin by PD patients and controls - a
finding fully consistent with our own report
on normal dietary content of riboflavin asso-
ciated with low plasma levels of FAD and
altered EGR-AC. The citations made by
Ferraz and associates demonstrate that they
have completely missed our point, even
though it was clearly emphasized even in the
title of our study (1). In addition to the
chapter by Tanner (Ref. 37 of our prelimi-
nary report, Ref. 1), neglected by Ferraz and
associates (while citing much older work by
the same group: their Ref. 7), recent work
has characterized the consumption of raw
meat (8) and high intake of iron (9) as risk
factors for PD.
Our inexpensive therapy (1) addresses
the cause of PD and, rather than merely
alleviating the symptoms (the major goal of
the costly palliative treatments available),
may provide partial disease regression even
in the more advanced stages and, when ad-
ministered to recent onset PD patients, may
even lead to the asymptomatic state. In addi-
tion, nobody can register patent rights for
riboflavin. Therefore, if properly considered
by patients and colleagues, the confirmation
of our results (allied to an early PD diagnosis
and identification of predisposed subjects)
may dramatically reduce the incidence of
this disease, thereby alleviating the related
burden on public and private health insur-
ance systems. Ferraz and associates may
best serve the interests of their questioning
patients and colleagues by conducting their
own study on this subject.
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